Rivaroxaban Concept

subject area of

• A Replacement for Warfarin  Academic Article
• A logical approach to surgical thromboprophylaxis  Academic Article
• A non-interventional comparison of rivaroxaban with standard of care for thromboprophylaxis after major orthopaedic surgery in 17,701 patients with propensity score adjustment  Academic Article
• A post-marketing assessment of major bleeding in total hip and total knee replacement surgery patients receiving rivaroxaban  Academic Article
• Accumulating data on rivaroxaban for venous thromboembolism in clinical practice  Academic Article
• Acute management of bleeding in patients on novel oral anticoagulants  Academic Article
• Advances in the management of venous thromboembolism.  Academic Article
• Advantages and limitations of the new anticoagulants  Academic Article
• After PCI with stents for AF, adding rivaroxaban vs warfarin to antiplatelet drugs reduced bleeding  Academic Article
• Analysis of patients with deep vein thrombosis switched from standard therapy to rivaroxaban in the non-interventional XALIA study  Academic Article
• Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors  Academic Article
• Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity  Academic Article
• Approach to the new oral anticoagulants in family practice: part 1: comparing the options.  Academic Article
• Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions.  Academic Article
• Aspirin or Rivaroxaban for VTE Prophylaxis after Hip or Knee Arthroplasty  Academic Article
• Assays for Measuring Rivaroxaban: Their Suitability and Limitations  Academic Article
• BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging study  Academic Article
• Balancing risk and benefit in venous thromboembolism trials: concept for a bivariate endpoint trial design and analytic approach  Academic Article
• Benefit–risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty  Academic Article
• Benefits and risks of extended treatment of venous thromboembolism with rivaroxaban or with aspirin  Academic Article
• Beyond Unfractionated Heparin and Warfarin  Academic Article
• Bleeding and antidotes in new oral anticoagulants  Academic Article
• Bleeding in patients with atrial fibrillation treated with dabigatran, rivaroxaban or warfarin: A retrospective population-based cohort study  Academic Article
• Bleeding with Direct Oral Anticoagulants vs Warfarin: Clinical Experience  Academic Article
• Bleeding with direct oral anticoagulants vs warfarin: clinical experience  Academic Article
• Characterization of Patients with Embolic Strokes of Undetermined Source in the NAVIGATE ESUS Randomized Trial  Academic Article
• Choosing wisely: The impact of patient selection on efficacy and safety outcomes in the EINSTEIN-DVT/PE and AMPLIFY trials  Academic Article
• Clinical Experience With the New Oral Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• Clinical implications of reversal agents for direct oral anticoagulants  Academic Article
• Comparative Pharmacodynamics and Pharmacokinetics of Oral Direct Thrombin and Factor Xa Inhibitors in Development  Academic Article
• Comparative safety of direct oral anticoagulants and warfarin in venous thromboembolism: multicentre, population based, observational study  Academic Article
• Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents  Academic Article
• Comparison of three-factor and four-factor prothrombin complex concentrates regarding reversal of the anticoagulant effects of rivaroxaban in healthy volunteers  Academic Article
• Cost-effectiveness of Dabigatran and Rivaroxaban Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation  Academic Article
• Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada  Academic Article
• Design of the rivaroxaban for heparin-induced thrombocytopenia study  Academic Article
• Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies  Academic Article
• Direct oral anticoagulants (DOACs) and pregnancy: A plea for better information  Academic Article
• Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.  Academic Article
• Direct oral anticoagulants for treatment of HIT: update of Hamilton experience and literature review  Academic Article
• Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis  Academic Article
• Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state  Academic Article
• Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism  Academic Article
• Enoxaparin Versus Dabigatran or Rivaroxaban for Thromboprophylaxis After Hip or Knee Arthroplasty  Academic Article
• Evolving use of new oral anticoagulants for treatment of venous thromboembolism  Academic Article
• Factor Xa and thrombin as targets for new oral anticoagulants  Academic Article
• Gastrointestinal bleeding with the new oral anticoagulants – defining the issues and the management strategies  Academic Article
• Higher-risk APS: do we dare to DOAC?  Academic Article
• How I treat heavy menstrual bleeding associated with anticoagulants  Academic Article
• How I treat target-specific oral anticoagulant-associated bleeding  Academic Article
• Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy  Academic Article
• Incorporating edoxaban into the choice of anticoagulants for atrial fibrillation  Academic Article
• International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants  Academic Article
• Is there a role for the novel oral anticoagulants in patients with an acute coronary syndrome? A review of the clinical trials  Academic Article
• Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants  Academic Article
• Laboratory Monitoring of Non–Vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation  Academic Article
• Laboratory measurement of the direct oral anticoagulants  Academic Article
• Less menorrhagia for women with VTE  Academic Article
• Long-term stroke and bleeding risk in patients with atrial fibrillation treated with oral anticoagulants in contemporary practice: Providing evidence for shared decision-making  Academic Article
• Low-dose rivaroxaban plus aspirin for the prevention of cardiovascular events: an evaluation of COMPASS  Academic Article
• Management consensus guidance for the use of rivaroxaban – an oral, direct factor Xa inhibitor  Academic Article
• Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study  Academic Article
• Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting  Academic Article
• Monitoring and reversal of direct oral anticoagulants  Academic Article
• Monitoring the anticoagulant effect after a massive rivaroxaban overdose  Academic Article
• NOAC monitoring, reversal agents, and post-approval safety and effectiveness evaluation: A cardiac safety research consortium think tank  Academic Article
• New Anticoagulants for Atrial Fibrillation  Academic Article
• New Anticoagulants for Treatment of Venous Thromboembolism  Academic Article
• New Anticoagulants for the Prevention of Thromboembolism  Academic Article
• New Antithrombotic Drugs: Potential for Use in Oncology  Academic Article
• New oral anticoagulant agents – general features and outcomes in subsets of patients  Academic Article
• New oral anticoagulants for stroke prevention in atrial fibrillation: impact of study design, double counting and unexpected findings on interpretation of study results and conclusions  Academic Article
• New oral anticoagulants for thromboprophylaxis in patients having hip or knee arthroplasty  Academic Article
• New oral anticoagulants in elderly patients  Academic Article
• New oral anticoagulants: not quite there yet  Academic Article
• New oral anticoagulants: which one should my patient use?  Academic Article
• Novel Oral Anticoagulants and the Risk of Major Hemorrhage in Elderly Patients With Chronic Kidney Disease: A Nested Case-Control Study  Academic Article
• Novel Oral Anticoagulants: A Focused Review for Stroke Physicians  Academic Article
• Novel Oral Factor Xa and Thrombin Inhibitors in the Management of Thromboembolism  Academic Article
• Novel oral anticoagulants in gastroenterology practice  Academic Article
• Novel oral anticoagulants in secondary prevention of stroke  Academic Article
• Optimizing the safety of treatment for venous thromboembolism in the era of the direct oral anticoagulants  Academic Article
• Oral Anticoagulant Therapy  Academic Article
• Oral Rivaroxaban for Symptomatic Venous Thromboembolism  Academic Article
• Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism  Academic Article
• Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives  Academic Article
• Oral anticoagulants in coronary heart disease (Section IV) Position paper of the ESC Working Group on Thrombosis – Task Force on Anticoagulants in Heart Disease  Academic Article
• Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement  Academic Article
• Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases  Academic Article
• Outcomes after catheter ablation and cardioversion in patients with non-valvular atrial fibrillation: results from the prospective, observational XANTUS study  Academic Article
• Outcomes of Temporary Interruption of Rivaroxaban Compared With Warfarin in Patients With Nonvalvular Atrial Fibrillation  Academic Article
• Overview of the New Oral Anticoagulants  Academic Article
• Patients with Peripheral Artery Disease in the COMPASS Trial  Academic Article
• Periprocedural antithrombotic and bridging therapy: recommendations for standardized reporting in patients with arterial indications for chronic oral anticoagulant therapy  Academic Article
• Pharmacologic Properties of the New Oral Anticoagulants: A Clinician-oriented Review with a Focus on Perioperative Management  Academic Article
• Population Pharmacokinetics and Pharmacodynamics of Rivaroxaban – an Oral, Direct Factor Xa Inhibitor – in Patients Undergoing Major Orthopaedic Surgery  Academic Article
• Potential of new anticoagulants in patients with cancer  Academic Article
• Practical aspects of new oral anticoagulant use in atrial fibrillation  Academic Article
• Practical guidance for using rivaroxaban in patients with atrial fibrillation: balancing benefit and risk  Academic Article
• Practical management of bleeding due to the anticoagulants dabigatran, rivaroxaban, and apixaban  Academic Article
• Prevention of thromboembolic complications in patients with superficial-vein thrombosis given rivaroxaban or fondaparinux: the open-label, randomised, non-inferiority SURPRISE phase 3b trial  Academic Article
• Procoagulants for management of bleeding with the new oral anticoagulants  Academic Article
• Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD)  Academic Article
• Rationale and design of XAMOS: noninterventional study of rivaroxaban for prophylaxis of venous thromboembolism after major hip and knee surgery  Academic Article
• Reduced-Intensity Rivaroxaban for the Prevention of Recurrent Venous Thromboembolism  Academic Article
• Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban  Academic Article
• Reversal of Direct Oral Anticoagulants: Current Status and Future Directions  Academic Article
• Reversal of direct oral anticoagulants: a practical approach  Academic Article
• Risk Stratification and Stroke Prevention Therapy Care Gaps in Canadian Atrial Fibrillation Patients (from the Co-ordinated National Network to Engage Physicians in the Care and Treatment of Patients With Atrial Fibrillation Chart Audit)  Academic Article
• Risk of recurrent venous thromboembolism according to baseline risk factor profiles  Academic Article
• Rivaroxaban compared with standard thromboprophylaxis after major orthopaedic surgery: co-medication interactions  Academic Article
• Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial  Academic Article
• Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source  Academic Article
• Rivaroxaban for Thromboprophylaxis After Fracture-Related Orthopedic Surgery in Routine Clinical Practice  Academic Article
• Rivaroxaban for stroke prevention in atrial fibrillation: a critical review of the ROCKET AF trial  Academic Article
• Rivaroxaban for the prevention and treatment of venous thromboembolism  Academic Article
• Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty  Academic Article
• Rivaroxaban for thromboprophylaxis after orthopaedic surgery: Pooled analysis of two studies  Academic Article
• Rivaroxaban for treatment of HIT: A riveting first experience  Academic Article
• Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study  Academic Article
• Rivaroxaban in Orthopedic Surgery — A Change of Paradigm?  Academic Article
• Rivaroxaban in Stable Cardiovascular Disease  Academic Article
• Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism  Academic Article
• Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial  Academic Article
• Rivaroxaban reversal with prothrombin complex concentrate or tranexamic acid in healthy volunteers  Academic Article
• Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Total Knee Arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin after total knee arthroplasty  Academic Article
• Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial  Academic Article
• Rivaroxaban vs. low molecular weight heparin for the prevention of venous thromboembolism after hip or knee arthroplasty: a cohort study  Academic Article
• Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease  Academic Article
• Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial  Academic Article
• Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial  Academic Article
• Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study  Academic Article
• Selective factor Xa inhibition for thromboprophylaxis  Academic Article
• Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment  Academic Article
• Strategy of continued vs interrupted novel oral anticoagulant at time of device surgery in patients with moderate to high risk of arterial thromboembolic events: The BRUISE CONTROL-2 trial  Academic Article
• The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE  Academic Article
• The Optimal Anti-Coagulation for Enhanced-Risk Patients Post–Catheter Ablation for Atrial Fibrillation (OCEAN) trial  Academic Article
• The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant Who Need an Elective Surgery or Procedure: Design and Rationale  Academic Article
• The effects of rivaroxaban on the complications of surgery after total hip or knee replacement  Academic Article
• The effects of timing of prophylaxis, type of anesthesia, and use of mechanical methods on outcome in major orthopedic surgery - subgroup analyses from 17,701 patients in the XAMOS study  Academic Article
• The prothrombin time does not predict the risk of recurrent venous thromboembolism or major bleeding in rivaroxaban-treated patients  Academic Article
• The top 4 advances in antithrombotic care in the last year  Academic Article
• Transition from apixaban to warfarin—addressing excess stroke, systemic embolism, and major bleeding  Academic Article
• Treatment of venous thromboembolism with dabigatran  Academic Article
• Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014  Academic Article
• Two doses of rivaroxaban versus aspirin for prevention of recurrent venous thromboembolism  Academic Article
• Ultrasound screening for asymptomatic deep vein thrombosis after major orthopaedic surgery: the VENUS study  Academic Article
• Venous thromboembolism management: where do novel anticoagulants fit?  Academic Article
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation  Academic Article
• XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation  Academic Article